

Haematologica
HAEMATOL/2015/139246
Version 1

Innovation in the prognostication of chronic lymphocytic leukemia –
how far beyond TP53 gene analysis can we go?

Sarka Pospisilova, Lesley-Ann Sutton, Jitka Malcikova, Eugen Tausch,
Davide Rossi, Emili Montserrat, Carol Moreno, Kostas Stamatopoulos,
Gianluca Gaidano, Richard Rosenquist, and Paolo Ghia

Disclosures: Sarka Pospisilova: none Lesley-Ann Sutton: none Jitka Malcikova: none Emili Montserrat: Advisor to Pharmacyclics; Advisor to Gilead, Spain; Advisor to ViVia Biotech, Spain; Scientific Committee: Janssen, Intl. Carol Moreno: none Kostas Stamatopoulos: none Eugen Tausch: none Davide Rossi: none Gianluca Gaidano: personal fees (Advisory Boards) from Novartis, Roche, Janssen, Gilead, Karyopharm, Morphosys, GlaxoSmithKline, Amgen, and Celgene. Richard Rosenquist: none Paolo Ghia: AbbVie, Adaptive Biotechnologies, Gilead, GSK, Incyte, Janssen, Pharmacyclics, Roche

Contributions: SP, LS, JM, EM, CM, KS, ET, DR, GG, RR and PG wrote the manuscript and provided comments.